Drug General Information (ID: DDIDRUNXY7)
Drug Name			Bevacizumab		Drug Info		Sunitinib		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Vegf/Vegfr Inhibitors				Antineoplastics

Mechanism of Bevacizumab-Sunitinib Interaction (Severity Level: Major)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Bevacizumab				Sunitinib
Mechanism		Increase risk of microangiopathic hemolytic anemia in combination with sunitinib				Sunitinib
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Sunitinib and Bevacizumab

Recommended Action
Management		Based on existing data, the use of bevacizumab in combination with sunitinib is not recommended.

References
1	Product Information. Avastin (bevacizumab). Genentech, South San Francisco, CA.
2	Bevacizumab + sunitinib associated with MAHA.?React. Wkly.?1211, 2 (2008).
3	Genentech Inc.Microangiopathic hemolytic anemia (MAHA) in patients treated with Avastin (Rm) (bevacizumab) and sunitinib malate. Internet Document: [2 pages], Jul 2009.